Molecular Profile Detail

Filtering

Case insensitive filtering will display rows if any text in any cell matches the filter term
Use simple literal full or partial string matches
Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
Click on any column header arrows to sort by that column
Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Clinical Trial	Phase	Therapies	Title	Recruitment Status	Covered Countries	Other Countries
NCT02693535	Phase II	Cobimetinib + Vemurafenib Atezolizumab + Talazoparib Regorafenib Larotrectinib Trastuzumab + Tucatinib Futibatinib Ipilimumab + Nivolumab Palbociclib Entrectinib Talazoparib Pembrolizumab Temsirolimus Pertuzumab + Trastuzumab Atezolizumab + Pertuzumab/trastuzumab/hyaluronidase-zzxf Abemaciclib Sunitinib Olaparib	TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer (TAPUR)	Recruiting	USA	0
NCT05216120	Phase II	Pemigatinib	Pemigatinib in Subjects With Adenosquamous Carcinoma of the Pancreas	Withdrawn	USA	0
NCT04233567	Phase II	Infigratinib	Infigratinib for the Treatment of Advanced or Metastatic Solid Tumors in Patients With FGFR Gene Mutations	Active, not recruiting	USA	0
NCT04003623	Phase II	Pemigatinib	Efficacy and Safety of Pemigatinib in Participants With Solid Tumors With FGFR Mutations or Translocations (FIGHT-208)	Terminated	USA	0
NCT06874335	Phase I	BHV-1530	A Phase 1 Study of BHV-1530 (AMB302) in Advanced Solid Tumors	Recruiting	USA	0
NCT02465060	Phase II	Erdafitinib Trametinib Crizotinib Sapanisertib Fexagratinib Dasatinib Osimertinib Palbociclib Capivasertib Larotrectinib Ulixertinib Nivolumab + Relatlimab Copanlisib Sunitinib Nivolumab Pertuzumab + Trastuzumab Ipatasertib Dabrafenib + Trametinib Binimetinib Adavosertib Afatinib Defactinib GSK2636771 Vismodegib Ado-trastuzumab emtansine Taselisib	Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)	Active, not recruiting	USA	2
NCT01831726	Phase II	Dovitinib	Dovitinib for Patients With Tumor Pathway Activations Inhibited by Dovitinib	Completed	USA	0
NCT06653777	Phase II	Pemigatinib	Efficacy of Pemigatinib in Patients With Solid Tumors Characterized by an Alteration of the Gene FGFR in Tumor Cells (AcSe PEMI)	Not yet recruiting	FRA	0
NCT04923126	Phase Ib/II	Mirdametinib	SJ901: Evaluation of Mirdametinib in Children, Adolescents, and Young Adults With Low-Grade Glioma	Recruiting	USA	0
NCT05627063	Phase I	ABSK121	A Study to Assess Safety, Tolerability, and Pharmacokinetics of ABSK121-NX in Patients With Advanced Solid Tumors	Recruiting	USA	1
NCT03834220	Phase II	Zoligratinib	Basket Trial in Solid Tumors Harboring a Fusion of FGFR1, FGFR2 or FGFR3- (FUZE Clinical Trial)	Terminated	USA \| ROU \| POL \| NOR \| NLD \| HRV \| GRC \| GBR \| FRA \| FIN \| ESP \| DNK \| CZE \| BRA \| BGR \| AUT \| AUS	6
NCT02706691	Phase II	Infigratinib	Pan FGFR Kinase Inhibitor BGJ398 in Treating Patients With FGFR1-3 Translocated, Mutated, or Amplified Recurrent Head and Neck Cancer	Terminated	USA	0
NCT01975701	Phase II	Infigratinib	A Phase 2 Study of BGJ398 in Patients With Recurrent GBM	Completed	USA \| NLD \| ESP \| CHE \| BEL \| AUS	0
NCT06302621	Phase I	Afatinib + Pemigatinib	Pemigatinib + Afatinib in Advanced Refractory Solid Tumors	Recruiting	USA	0
NCT04003610	Phase II	Pembrolizumab + Pemigatinib Pembrolizumab Carboplatin + Gemcitabine Pemigatinib	Pemigatinib + Pembrolizumab vs Pemigatinib Alone vs Standard of Care for Urothelial Carcinoma (FIGHT-205)	Terminated	USA \| SVK \| ROU \| POL \| ITA \| IRL \| GBR \| FRA \| FIN \| ESP \| DEU \| CAN \| BEL \| AUT	2
NCT03611868	Phase Ib/II	Alrizomadlin + Pembrolizumab Alrizomadlin	A Study of APG-115 in as a Monotherapy or Combination With Pembrolizumab in Patients With Metastatic Melanomas or Advanced Solid Tumors	Recruiting	USA \| AUS	0
NCT04096417	Phase II	Pemigatinib	Pemigatinib for the Treatment of Metastatic or Unresectable Colorectal Cancer Harboring FGFR Alterations	Active, not recruiting	USA	0
NCT04601857	Phase II	Futibatinib + Pembrolizumab	Futibatinib and Pembrolizumab Combination in the Treatment of Advanced or Metastatic Urothelial Carcinoma	Active, not recruiting	USA \| FRA \| ESP	0
NCT04294277	Phase II	Pemigatinib	Safety and Efficacy of Pemigatinib in Patients With High-risk Urothelial Cancer After Radical Surgery (PEGASUS)	Terminated	ITA	0
NCT04189445	Phase II	Futibatinib	Futibatinib in Patients With Specific FGFR Aberrations	Completed	USA \| TUR \| SWE \| NLD \| ITA \| GBR \| FRA \| ESP \| DEU \| BEL	5
NCT04197986	Phase III	Infigratinib	Study of Oral Infigratinib for the Adjuvant Treatment of Subjects With Invasive Urothelial Carcinoma With Susceptible FGFR3 Genetic Alterations	Terminated	USA \| NLD \| ITA \| GRC \| GBR \| FRA \| ESP \| DEU \| CAN \| BGR \| BEL	0
NCT05267106	Phase II	Pemigatinib	Study to Evaluate the Efficacy and Safety of Pemigatinib in Participants With Previously Treated Glioblastoma or Other Primary Central Nervous System Tumors Harboring Activating FGFR1-3 Alterations (FIGHT-209)	Completed	USA \| NLD \| ITA \| GBR \| FRA \| ESP \| DNK \| DEU	1

Profile Name	FGFR3 rearrange
Gene Variant Detail	FGFR3 rearrange (unknown)
Relevant Treatment Approaches

Molecular Profile Detail

Contact

Filtering

Sorting